MedSurg

MedSurg:
Category Leadership & Growth Drivers
Urology and
Endoscopy Neuromodulation
Pelvic Health
Stone Disease & Precision Spectra
SpyGlass DS
LithoVue Single-Use Visualization Precision Novi
Ureteroscope Optimizes pancreatico- Leading SCS platforms,
Leading platform, next biliary procedural Illumina 3Dsoftware &
gen technology, and efficiency & productivity non-rechargeable
expanding globally system

Endoluminal Surgery -
Mens Health Oncology
Category leadership, Endoscopic resection of
market & geographic lesions in colon,
expansion esophagus or stomach
Vercise PC DBS
System & Cartesia
Directional Lead
1st Directional System for
Parkinsons, dystonia, &
tremor globally; U.S. DBS
launch YE2017E

Womens Health Infection Control & RF Ablation

Expanding portfolio Pathology Services Comprehensive range
technologies & Solutions for Ambulatory solutions for pain
global footprint Surgery Center market management
 MedSurg
Urology & Pelvic Health
Dave Pierce
Senior Vice President and President, Urology & Pelvic Health
 Urology & Pelvic Health Vision 2020+
Imagine a world where
Surgeons worldwide have access to flexible ureteroscopy
procedures to treat patients with stone disease and also
utilize new approaches to stone procedures that reduce
the cost of care per patient

Patients are educated and empowered to take

advantage of all treatment options for erectile
dysfunction

Minimally invasive procedures are the standard of care

and fully replace hysterectomy for women with benign
gynecological conditions

44
 Leadership in Urology & Pelvic Health

Market Factors BSX Growth Drivers

Innovative new products,
Demographics and disease clinical programs, and
prevalence (age, obesity, patient education
diabetes, vascular disease)
Global expansion and focus
Specialized therapeutic on emerging markets
interventions increasing
device utilization Compelling opportunities in
adjacent markets
Increasing patient access
Tuck-in M&A

Market BSX
2016 Size Growth 2016-2020 est. CAGR Revenue Share Position Growth*

~$3.5B +5% +5% - 6% $1.0B #1 +14%

(ex. AMS)

*Growth in constant currency, excluding the impact of the AMS Male Urology portfolio acquisition
55
 Large and Growing Markets

Stone Disease Mens Health Womens Health

$1.3B Market $700M Market $1.5B Market
+5-7% Growth +4-6% Growth +4-6% Growth
6% of the population 15M men worldwide 35% of women worldwide
worldwide affected by affected by urinary affected by urinary
kidney stone disease1 incontinence2 incontinence4

High BMI significantly 50% of men age 50+ 12% of reproductive-aged

increases risk of kidney affected by benign women affected by
stone development prostatic hyperplasia3 abnormal uterine bleeding5

66
 Category Leadership in Stone Disease
Committed to Lead LithoVue - Transforming fURS
Innovative single-use technology that is transforming
$1.3B global market
flexible ureteroscopy (fURS)
1) The most Comprehensive Device Portfolio
for the clinical management of stone disease Rapid technology uptake
800+ hospitals globally
10,000+ procedures
30+ posters, abstracts and publications
2) Clinical Education and Training Driving growth with pull-through
Stone Institute Workshops
Preceptor Training Center of Excellence Programs
Preceptorship and Proctorship Training Programs
LithoVue delivers
tangible financial
3) Partnerships to Drive Clinical Evidence and clinical benefits

77
 LithoVue: Physicians Perspective

88
 LithoVue: Transformational Technology

Today
Economic benefits: Establish LithoVue as
standard of care for complex stone
procedures
OR efficiency: Greater throughput
increasing procedural volume
Pull through: $0.40 for every $1 of LithoVue
sales

No repairs. Tomorrow
Economic evidence drives greater
No sterilization. utilization for routine stone procedures
No compromise. Greater global access to flexible
ureteroscopy advances care worldwide

99
 Revitalized Focus in Mens Health to Expand
Global Reach

Strengthening Leadership Spotlight on Erectile Dysfunction

$700M global Mens Health market Leading with 70% global market share

15K+ patients
Erectile Dysfunction (ED): $250M MC treated annually
Incontinence (MC): $150M BPH
BPH: $300M ED 50% of men over age 40 are affected by
some degree of Erectile Dysfunction1
Expanding Global Reach
Untreated ED associated with severe
Portfolio innovation Physician training Patient awareness problems including anxiety and depression

Main causes of Erectile Dysfunction

40% vascular causes 15%
Other
Accelerating Patient Education 30% diabetes* related 40%
15% Rx Vascular
FIXincontinence.com 15% prescription medication
and Edcure.org 15% other causes 30%
500,000+ patient Diabetes
*Diabetic men develop ED 10 to 15 years earlier
sessions in 2016 than men without diabetes2
10
10
10
 Continued Innovation in Womens Health to
Drive Procedural Adoption

Strengthening Leadership Spotlight on Tissue Resection in GynSurg

$1.5B global Womens Health market Up to 40% of reproductive-aged women will develop
uterine fibroids or polyps1

GynSurg: $1.1B
PF Symphion
Pelvic Floor (PF): $400M
System
GynSurg Resectr
Focus on Innovation
Clinical data Surgical training Expanding product portfolio

Hysteroscopic Resection Procedures (U.S.)

+11%

Physician Education and Training

Pelvic Floor Institute 120+
Clinical training physicians
Economic tools collaborating
Patient education on research 2015 2016 2017E 2018E 2019E 2020E
Expanding Globally through Stone Leadership
Leading with Stone Strong International Revenue Growth
Leverage stone to expand leadership and
strengthen capabilities globally
Under-represented internationally

2016 Revenue
International: ~$300M Intl
U.S.: ~$700M
U.S.

Stone Disease International Revenue Growth

Deliver physician education and clinical training $450M
Innovate to meet market needs
$300M
Drive LithoVue momentum

Womens and Mens Health

Deliver physician education and clinical training
Strengthen commercial capabilities 2016 2017E 2018E 2019E 2020E
Build patient awareness Stone Disease Men's Health Women's Health
12
 Compelling Opportunities in Adjacent Markets
$7.0B
Key Growth Drivers
Core Markets $2.6B
New Adjacencies Accelerate into new adjacencies
Market Expansion
Expanding visualization
Urologic cancer
Overactive bladder
$4.4B
Core Growth

Drive above market growth in the core

$3.5B Stone Disease leadership
Globalization in developed and
emerging markets

2016 2020E
13
13
13
 Urology & Pelvic Health:
Leadership in Large and Growing Markets

$3.5B UroPH market has strong growth and favorable demographics

BSX is $1B category leader, outpacing the market and led by:

Portfolio of leading technologies

Disruptive, innovative new products

Strong international growth, led by kidney stone franchise

Compelling adjacent market opportunities

14
14
14
 References
Slide 4 (Large and Growing Markets):
1. Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-15.
2. National Health and Nutrition Examination Survey 20012010.
3. Benign Prostatic Hypertrophy. American Urological Association. 2016. www.auanet.org/education/benign-prostatic-
hypertrophy.cfm www.auanet.org/education/benign-prostatic-hypertrophy.cfm. Accessed May 20, 2016.
4. Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary
incontinence. Obstet Gynecol. 1997 Apr;89(4):501-6.
5. Spencer CP, Whitehead MI. Endometrial assessment revisited. Br J Obstet Gynaecol. 1999 Jul;106(7):623-32.

Slide 8 (Revitalized Focus in Mens Health to Expand Global Reach):

1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial results of the
Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61.
2. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009 May;6(5):1232-47.

Slide 9 (Continued Innovation in Womens Health to Drive Procedural Adoption):

1. Okolo S: Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008, 22: 571-
588. 10.1016/j.bpobgyn.2008.04.002.

15
15
15
 MedSurg
Endoscopy
Art Butcher
Senior Vice President and President, Endoscopy
Endoscopy Vision 2020+
Imagine a world where
Accurate, timely diagnosis using interventional
imaging catheters slows the progression of
pancreatic cancer and other GI diseases

Minimally invasive, early endoscopic intervention

reduces costly surgery of the esophagus, stomach
and colon, enabling patients to recover more quickly

Infection prevention measures in the GI lab reduce

antibiotic resistant infections, saving patient lives
and delivering healthcare savings
World Leader in Flexible Endoscopy Devices

Market Factors BSX Growth Drivers

Large, diverse markets with Device portfolio is expanding the
significant disease burden and market
increasing device utilization
Category leadership driving core
Endoscopic procedures and business faster + new
devices are attractive adjacencies accelerate growth
alternatives to surgery and Rx
Globalization & Emerging
Growing specialization of Markets
medical and surgical
endoscopists Tuck-in M&A

Market BSX
2016 Size Growth 2016-2020 est. CAGR Revenue Share Position Growth*

~$3.0B +5% +5% - 6% $1.4B #1 +10%

*Growth in constant currency

Doubling Our Served Markets By 2020
$7.0B
Key Growth Drivers
Core Markets $3.5B
New Adjacencies
Market Expansion Accelerate into new adjacencies
Pathology
Infection Prevention
Endoluminal Surgery

$3.5B
Core Growth

$3.0B Drive above market growth in core

Biliary Disease Intervention
Pulmonary Disease Intervention

2016 2020E
Category Leadership in Large and Growing
Markets + Broadening into Adjacencies
Market Market
2016E 2020E Key Accelerators

Pancreaticobiliary EUS* indications

$1.2B $1.5B Imaging
Disease Surgery to Endoscopy

Gastrointestinal Pathology
$800M $2.0B Cancer ablation
Cancer Endoluminal surgery

Gastrointestinal Clipping adoption

$600M $1.0B Closure
Bleeding Ingestible technology

Infection Prevention Compliance kits

$300M $2.0B Scope valves and repair
& Other** Procedural devices

Asthma
Pulmonary $100M $500M Lung cancer

~$3.0B ~$7.0B *EUS = Endoscopic Ultrasound **Other includes Enteral Access and Scope Repair
Transforming the Standard of Care
SpyGlass DS System

First and only minimally invasive, single-use, single operator digital cholangioscope

Compelling outcomes and data

30,000+ patients in 50+ countries
Accurate, real-time diagnosis
>90% stone clearance success rates
Changes clinical management in 64% of patients
relative to traditional diagnostic approaches

1M+ ERCPs annually

Stricture Pancreatic Stone
duct
Transforming the Standard of Care
AXIOS

Revolutionary stent designed specifically for EUS* guided transluminal therapy

Current indications: Possible new indications: Gallbladder

Bile Duct

Gallbladder (EU) Gallbladder (US)

Pseudocyst drainage Gastric Outlet Obstruction
Walled-off necrosis Type II Diabetes
Bile duct drainage (EU) Obesity
Small Intestine

High growth segment

within the biliary market

*EUS = Endoscopic Ultrasound

Accelerating into New Adjacencies
Valuable Solutions for the GI Practice & Patients

Pathology Services Infection Prevention

$600M Ambulatory Surgery Center market (U.S.) $775M global market
Dedicated commercial team servicing Antibiotic resistant infections cost the U.S.
1,700 GI Ambulatory Surgery Centers $20 billion each year

8.5M biopsies each year

Market leading RJ4
biopsy forceps

The only U.S. lab with GI

Enhanced safety for patients and
pathology specialists
healthcare providers
Improves DX accuracy
Ensures compliance with infection
control guidelines
Next day, secure
electronic data transfer Improves operational efficiency and
Improves efficiency inventory control
Evolution of Minimally Invasive Surgery
Open Surgery Laparoscopic Surgery Endoluminal Surgery

17% of patients undergoing surgery for complex polyps experience

significant adverse events and 13% require readmission1
Surgical Resection (n=731) Endoscopic Resection (n=1981)
Length of Stay 5 days 0 days
12 Month Mortality 1.4% 0
Hospital Costs $15K $2K
Hospital Charges $53K $15K
Accelerating into New Adjacencies
Endoluminal Surgery

Endoluminal surgery is emerging as alternative to surgical resection of cancer or pre-cancer

GI Cancer Worldwide Prevalence
2.8M gastrointestinal cancers
92% of colonic pre-cancer /
11-22M adenoma (pre-cancer)
6M Barretts Esophagus (pre-cancer)
cancer surgical resections
could have been managed
endoscopically

Esophageal Stomach Colorectal Pre-cancers

BSX will lead with a comprehensive portfolio of devices for the Surgical Endoscopist

Lifting* Cutting Graspers* Traction* Closure

*Expected to be available in 2018

Endoluminal Surgery at Work
Endoscopy: Category Leader + Meaningful
Market Expansion

Track record of consistent high performance, outpacing our markets

Exciting growth sector with compelling outlook/shift to minimally invasive

techniques

Several significant market expansion opportunities in play to accelerate the

business

Clear category leadership, deep portfolio, multiple platforms

Margins accretive to BSX

Aiming for $2B in revenue in 2020

References
Slide 9 (Evolution on Minimally Invasive Surgery)
1. Gastroinest Endosc 2016; 84:296-303
 MedSurg
Neuromodulation
Maulik Nanavaty
Senior Vice President and President, Neuromodulation
 Neuromodulation Vision 2020+
Imagine a world where
25M+ patients suffering from chronic neuropathic pain
receive personalized therapy, giving them their lives
back, at every moment, every day

A smart, connected, ecosystem transforms the current

surgical practice and optimizes outcomes for movement
disorder patients

New targeted therapy options exist for patients with

stroke (2M+) and other neurodegenerative disorders
(10M+)
Positioned for Leadership in a Fast Growth Market

Market Factors BSX Growth Drivers

SCS MultiWave platform:

Highly underpenetrated Illumina 3D
market MRI: Montage
LUMINA data
Low patient awareness
DBS franchise
Technology evolution Vercise PC Directional
Unmet clinical needs Vercise Gevia MRI Directional

Global expansion Clinical programs

International expansion

Market BSX
2016 Size Growth 2016-2020 est. CAGR Revenue Share Position Growth*

~$2.5B +10% +8% - 12% $560M #2 +12%

*Growth in constant currency

Pain (SCS): Expanding a Winning Pain Portfolio
and Leading with Rigorous Clinical Research
Spectra SCS Broadest Lead
Illumina 3D Systems Portfolio Multiwave Cosman

Options for Patients

Precision with Neural (32 contacts, MRI Unrivaled Flexibility and
compatibility1, Non- Personalized Therapy RF Ablation
Targeting Algorithm Coverage
Rechargeable)

15+ ongoing clinical research studies and RCTs2 to help prove personalized therapy is the future of pain relief:
PROCO3 (Q2-17): Double-blind crossover RCT to evaluate the role of frequency on SCS patient outcomes
WHISPER4 (Q4-17): Crossover RCT to evaluate the effectiveness at sub-perception amplitude
ACCELERATE5 (H2-18): Crossover RCT to evaluate the safety and effectiveness at high-rate SCS
RELIEF6 (on-going): Global registry to evaluate long-term real world outcomes

Strong cadence of technology with 2 new platforms launching over next 24 months
Pain (SCS): Future of Pain Relief =
Personalized Waveform Therapy

60% of Patients Use Patients Prefer Their Own Multiple Waveforms Achieve
Multiple Waveforms Individualized Stim Patterns Excellent Pain Reduction

2 10
8 D = 6.2

Numeric Rating
8
40%
4

Scale (NRS)
1 khz
14
7.9
standard

Patient #
Burst
6
28
rate only
Anode
Intensificatio
17 n/ 4
Prism
23
Standard
18 Rate 2
60% used novel
16 1.7
stim waveforms 0
9
Baseline NRS Follow-up NRS

Change in pain score at mean 180 days

Registry retrospective study on waveform Case study of individual patients post-implant using standard rate (16%),
use at least 20% of the time1 n=250 waveform use over one week1 n= 30 1kHz (61%), and both combined (13%)2
n= 77

With Illumina 3D and Multiwave, Spectra is the only SCS platform designed to
deliver the Right Waveform and stimulate the Right Target at the Right Time
 Pain (SCS): Neural Targeting Algorithm (Illumina 3D)
Delivers Superior Long Term Results

2 year LUMINA Data1 published in Pain Medicine, January 2017

10.0
8.75
9.0 Previous Generation System
8.0 7.17 D = 4.23 D = 5.34
Numeric Rating Scale (NRS)

7.0 100%
6.0 81%
5.0
80% 74% 71%

Responder Rate
4.0 3.21 2.92 2.96 2.94 3.35 3.30 3.02 3.41 63%
3.0
2.0
60% 51%
1.0
41%
0.0 40%

20%
(N=141) (N=169) (N=47) (N=34) (N=45) (N=73)
0%
OVERALL PAIN at LEG PAIN at 24 BACK PAIN at 24
ALL PATIENTS SEVERE PATIENTS 24 months months months

Illumina 3D delivered sustained pain relief in real world patients and demonstrates
superior outcomes vs. a previous generation system
 Pain (SCS): PROCO RCT True Level 1 Study
2017 INS Congress in May 2017

The PROCO RCT1 Study Background and Outcomes

10 Background:
Back pain results (n = 20, p = .00002) Double blind, crossover, multicenter study comparing 1kHz vs. 4kHz vs.
9
7kHz vs. 10kHz
8 Key inclusion criteria: persistent lower back pain for > 90 days and
6.77 lower back pain NRS 5
7
E-diary prompted each patient for 180 data points
6 Supported by multiple years of mechanism of action research (pre-
clinical)
5
Outcomes:
Mean NRS (e-diary)

4 3.48 3.34
3.11 3.21 Frequencies from 1-10 kHz provide similar pain relief when proper neural
3 dosing is used to optimize therapy
1 kHz provides excellent pain relief at 1/3 the charge of higher frequencies
2
Patients need multiple options:
1 No single waveform can treat all patients
A system should provide precise targeting over 3 or more vertebral levels
0
Baseline 1 kHz 4 kHz 7 kHz 10 kHz

When using proper targeting Frequency is NOT the determinant factor

and neural dosing algorithm: BSX 1kHz uses two-thirds less energy with equivalent outcomes
Brain (DBS): Revolutionizing Brain Modulation Therapy

Vercise DBS Systems Brainlab Visualization Smart Programming

Precision Control of Directionality Personalizes Programming for

Advanced Surgical Planning Captures Outcomes
with MICC* Patients

BSX best-in-class system solution to meet market needs:

High-growth, underpenetrated market
~$600M worldwide market shifting away from a single player market

BSX poised to enter U.S. in late 2017/early 2018 with compelling new technology

System capabilities to potentially treat other neurological disorders

*MICC = Multiple Independent Current Control

Physicians Take: The Power of Vercise
Brain (DBS): Driving Superior Outcomes with Vercise

Highest quality of life improvement First to introduce system flexibility designed to

at 6 months and 3 years expand therapeutic window
Percentage Improvement in QOL (%)

Conventional Therapy

Mean Amplitude (mA) Range

Vercise Therapy
Stimulation
Induced Side
Stimulation
6 Effect 6.87
Induced Side D = -2.2 mA
D = +1.5 mA
Effect (-41%)
(+64%)
4
4.63
2 3.05
0
Therapeutic Window Stimulation Induced Side
Effects Window
VANTAGE Study
Lancet Neurology 2015 and Neurosurgery 2016 CUSTOM-DBS Study4 MDS 2014

Vercise MICC platform is the most flexible DBS system designed to improve
patient outcomes and minimize side effects
 Path to Leadership in Brain Modulation:
Technology Backed By Clinical Evidence
U.S. launches of
Vercise PC and New
Vercise Gevia Indications

Next Generation
System

Vercise PC First Directional System with

integrated Clinical Effects Map (EU)1 Anticipated U.S. approval of MRI, Personalized Visualization
Vercise Gevia First MRI conditional 1st gen (non-directional) system3
Rechargeable Directional System (EU)2

Today 2018 2019 2020+

18+ ongoing clinical research studies4 helping drive Brain Modulation to be a meaningful contributor to BSX:

INTREPID5 (Q4:17) : First & only prospective, double-blind multi-center RCT; evaluating Vercise DBS System for U.S. entry
DBS Directional6 (2019): Evaluating therapeutic advantages of Cartesia Directional Lead w/Vercise PC DBS System
DBS Registry7 (on-going): First comprehensive registry of real world outcomes to establish improvement in quality of life
Neuromodulation:
Strong Growth Driven by Leading Innovation

Exciting large, underpenetrated and high-growth markets (SCS & DBS)

Pain SCS expanding leadership footprint through personalized therapy

Broadest portfolio: neural targeting algorithms and waveforms, MRI, primary cell, 32 contacts, RF
Commitment to rigorous clinical and pre-clinical research: LUMINA, WHISPER, PROCO, ACCELERATE
Significant international expansion opportunity

Brain DBS franchise poised for accelerated share gains with the most innovative
platforms
Winning directional system supported by extensive clinical data
Integrated offering: Directional System, visualization, MRI, Brainlab partnership
U.S. launch targeted end of 2017/early 2018

Convergence of technology and clinical insights unlocking new treatments for

neurological disorders (Stroke, OCD, Depression, Alzheimers, and others)
References
Slide 4 (Pain (SCS): Expanding a Winning Pain Portfolio and Leading with Rigorous Clinical Research):
1. 1.5 Tesla MRI conditional when all conditions of use are met
2. Includes company and investigator-sponsored research studies
3. Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes (PROCO) NCT02549183
4. Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude (WHISPER) NCT02314000
5. Safety and Effectiveness Study of the Precision SCS System Adapted for High-Rate Spinal Cord Stimulation (ACCELERATE) NCT02093793
6. RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain (RELIEF) NCT0171905

Slide 5 (Pain (SCS): Future of Pain Relief = Personalized Waveform Therapy):

1. Clinical Application of Novel Neurostimulation Waveforms Using a Single Spinal Cord Stimulation Device: A Real-World Device Utilization
Registry Presented by Anthony Berg, MD at WVSIPP 2016
2. Improved Spinal Cord Stimulation Outcomes Associated with Percutaneous Lead Placement and Multiple Waveform Programming Technique,
Pyles et al., Poster Presentation, INS 2017
Slide 6 (Pain (SCS): Neural Targeting Algorithm (Illumina 3D) Delivers Superior Long Term Results):
1. Veizi et al, SCS with Anatomically Guided (3D) Neural Targeting Shows Superior Chronic Axial Low Back Pain Relief Compared to Traditional
SCS. Pain Medicine Jan 2017.

Slide 7 (Pain (SCS): PROCO RCT - True Level 1 Study in SCS):

1. Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes (PROCO) NCT0254918
References
Slide 10 (Brain (DBS): Driving Superior Outcomes with Vercise):

1. Vantage:
1 Year: Timmermann et al., Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinsons disease (the VANTAGE study): a non-randomised,
prospective, multicentre, open-label study Lancet Neurology 2015; 14: 693701

3 Years: Timmerman et al, Three-Year Outcomes of a Prospective, Multi-center Trial Evaluating Deep Brain Stimulation With a New Multiple-Source, Constant-Current
Rechargeable System in Parkinson Disease. Neurosurgery. Aug 2016.

2. VA Study: Follett et al., Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease. NEJM 362;22; Weaver et al., 2012
Randomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomes, AAN

3. Deuschl 2006: A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease. NEJW 355;9

4. CUSTOM-DBS: Volkmann et al., Presented at 2014 Annual Meeting of the International Parkinson and Movement Disorders Society, June 2014
References
Slide 11 (Path to Leadership in Brain Modulation: Technology Backed By Clinical Evidence) :

1. Vercise PC System, Vercise Gevia System, and Cartesia Directional Lead: CE Marked. Not available for use or sale in the U.S.
2. 1.5 Tesla MRI conditional when all conditions of use are met
3. Vercise System: CE Marked. Caution: Investigational Device. Limited by US federal law to investigational use only. Not available for sale in the
U.S.
4. Includes company and investigator-sponsored research studies
5. Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease (INTREPID) NCT01839396
6. Directional Data:
Steigerwald et al. Directional deep brain stimulation of the subthalamic nucleus: a pilot study using a novel neurostimulation device. Movement Disorders. 2016;

Reker et al, Directional deep brain stimulation: A case of avoiding dysarthria with bipolar directional current steering: Parkinsonism and Related Disorders 2016 Aug

Scientists Test Next Generation Deep Brain Stimulation Leads to Improve Targeting the Subthalamic Nucleus with Fewer Adverse Effects NEUROLOGY TODAY | Jul
2016

7. Registry of Deep Brain Stimulation With the VERCISE System: Vercise DBS Registry NCT02071134
Q&A